Chemours (NYSE: CC) reported Q4 EPS of $0.81, $0.12 worse than the analyst estimate of $0.93. Revenue for the quarter came in at $1.6 million versus the consensus estimate of $1.57 million.

GUIDANCE:

Chemours sees FY2022 EPS of $4.07-$4.70, versus the consensus of $4.54.

For earnings history and earnings-related data on Chemours (CC) click here.